MacroGenics, Inc. (NASDAQ: MGNX) provided an update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate (ADC) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE